If you are sourcing Crospovidone XL 10 for tablet formulations, the fastest way to evaluate it is to look at three things: its disintegration performance, its physical specification, and whether the supplier can provide consistent documentation and batch-to-batch stability. In most B2B projects, Crospovidone XL 10 is considered as a superdisintegrant for direct compression, wet granulation, and orally disintegrating tablet applications. In this guide, I explain what Crospovidone XL 10 is, its uses, key specification points, and how I would buy and qualify it for formulation or procurement work.
Crospovidone XL 10 is a crosslinked polyvinylpyrrolidone used mainly to help tablets break apart quickly after contact with liquid. Buyers usually evaluate it by particle size, moisture, swelling behavior, flowability, and documentation such as COA, SDS, and TDS. For procurement, I recommend confirming the intended dosage form, the target disintegration profile, the intended process route, and supplier consistency before placing volume orders. If you need a quotation or sample, it is best to request specification confirmation first so the material matches your formulation goal.
Crospovidone XL 10 is what I would describe as a functional excipient designed to support rapid tablet disintegration. It belongs to the crospovidone family, which is widely used in pharmaceutical and nutraceutical formulations where fast break-up in liquid is important. In practical sourcing terms, XL 10 usually refers to a specific grade or particle-size related designation, so the exact performance should always be confirmed with the supplier’s technical data.
This guide is written for formulation teams, procurement teams, and technical evaluators who need to compare grades, check compatibility, and reduce buying risk. I focus on what matters most in a B2B setting: specification, functional value, common uses, and the questions to ask before buying. If you are comparing suppliers, this page is meant to help you screen faster and communicate more precisely.
According to the U.S. Food and Drug Administration’s Inactive Ingredient Database and official excipient references, crospovidone is a recognized pharmaceutical excipient used in oral solid dosage forms. That makes it especially relevant when the buyer needs both performance and regulatory discipline. For safety and compliance, final use should always be matched to the target market and product registration route. Source: U.S. FDA Inactive Ingredient Database; USP-NF excipient monographs.
When I review Crospovidone XL 10, I focus on the specification dimensions that affect processing and final tablet performance. The grade name alone is not enough, because two suppliers may label a similar product differently while still offering different particle distribution or flow behavior. A serious buyer should ask for the technical data sheet and compare the actual measured values, not only the marketing description.
| Specification Dimension | Why It Matters | What to Confirm |
|---|---|---|
| Appearance / physical form | Helps with handling, blending, and process consistency | Powder color, odor, bulk form |
| Particle size distribution | Affects flowability, segregation risk, and disintegration efficiency | D10, D50, D90 or sieve range |
| Moisture content | Influences storage stability and formulation behavior | Maximum moisture % and test method |
| Swelling capacity / water uptake | Directly connected to disintegration performance | Supplier test method and typical result |
| Flowability | Important for direct compression and blending | Angle of repose, bulk density, tapped density |
| Packaging | Impacts storage, handling, and contamination control | Bag size, liner type, palletization |
For operational planning, I would also confirm the batch size, shelf life, and storage requirements. In many excipient programs, packaging may be offered in 10 kg, 20 kg, or 25 kg bags, but buyers should verify the actual offered format with the supplier. Storage is typically expected in a cool, dry environment, and many procurement teams ask for a shelf life statement of 24 months or similar if supported by the manufacturer’s stability data. These values must always be confirmed on the actual COA or TDS, because they can vary by producer and market.
From a formulation perspective, particle size and moisture control are often as important as chemical identity. Smaller or more optimized particle distributions can improve mix uniformity, but they may also affect dusting or handling behavior depending on the process. Because of that trade-off, I recommend asking for both analytical data and process guidance before switching suppliers. Source: United States Pharmacopeia (USP) excipient standards; FDA excipient guidance resources.
The main reason buyers choose Crospovidone XL 10 is its disintegration function. In simple terms, it helps tablets absorb water, swell, and break apart more efficiently after ingestion or in a test medium. That can support faster release of the active ingredient and improve usability in orally disintegrating or rapidly disintegrating products.
Functionally, crospovidone works differently from binders or fillers. It is usually not selected to make tablets harder or longer lasting; instead, it is selected to improve breakup without necessarily increasing tablet mass significantly. For formulation teams, this makes it a valuable tool when balancing hardness, friability, disintegration time, and dissolution behavior. In many projects, the target is not just “fast,” but “fast and repeatable.”
There are also manufacturing benefits. A well-chosen crospovidone grade can help reduce the risk of delayed disintegration caused by overly dense compression or hydrophobic APIs. It can also support more robust processing in direct compression systems, where powder flow and compactibility matter. That said, the final result depends on the whole formula, not only on the excipient itself.
In many oral solid dosage applications, superdisintegrants are used at roughly 2% to 5% of tablet weight, although the final loading depends on the active ingredient, tablet size, compression force, and target disintegration time. For this reason, buyers should not treat one dosage level as universal. I suggest treating supplier recommendations as a starting point for lab evaluation rather than a final formula instruction. Source: FDA/USP excipient references and published formulation literature on superdisintegrants.
Uses for Crospovidone XL 10 are most commonly centered on oral solid dosage forms. It is often considered for conventional tablets, directly compressed tablets, fast-dissolving tablets, chewable formats, and some capsule-fill systems where rapid breakup is needed after administration. The exact suitability depends on the API, process route, and required release profile.
In pharmaceutical formulation, it is commonly used in products where disintegration speed matters more than prolonged tablet integrity in the stomach. In nutraceutical and vitamin tablets, it can help improve user experience by reducing the time it takes for the dosage form to fall apart. In some over-the-counter applications, this can improve convenience, especially when the tablet is intended for easy swallow or rapid onset.
For buyers in the chemical and pharmaceutical supply chain, the most useful question is not simply “what is it used for?” but “what problem does it solve in my formula?” Crospovidone XL 10 is typically chosen when the formula needs faster wetting, faster breakup, or better disintegration reproducibility. If your product already disintegrates well, the grade may still be useful, but the value proposition becomes more process-specific.
Because crospovidone is a functional excipient, application matching should always consider the target dissolution behavior and the full excipient system. A grade that performs well in one formulation may not be the best choice in another, even if the API is similar. That is why I recommend sample testing under your actual compression settings rather than relying on a general grade description alone. Source: Pharmacopeial excipient references and formulation development literature.
If I were qualifying Crospovidone XL 10 for procurement, I would start with the intended product format and then work backward to the required material behavior. The process should be practical and evidence-based. You want a material that is suitable for your formula, easy to handle in production, and stable enough to buy repeatedly.
There are a few decision points that matter more than others. First, confirm whether your formula is sensitive to particle size variation. Second, decide whether you need the grade for direct compression or for granulated systems. Third, check whether your regulatory pathway requires specific compendial alignment. Those three checks often prevent most sourcing mistakes.
One common mistake is choosing a crospovidone grade only by price. Another is assuming all crospovidone grades behave the same in compression. A third is skipping a pilot test and going straight into commercial purchase. These shortcuts can lead to slower disintegration, higher reject rates, or unnecessary reformulation.
If you are looking for more details, kindly visit Yuking.
I recommend testing the material at the same compression force and blending time you plan to use in production. If possible, compare at least two samples or grades side by side using the same API and process settings. This usually gives a more reliable view of performance than reading specification sheets alone. Even a small difference in particle size or moisture can influence final tablet behavior.
For B2B buyers, quality documents are not optional. At minimum, I would expect COA, SDS, and TDS for every quotation stage and certainly before bulk purchase. Depending on your market, you may also need statements related to compendial status, allergen information, traceability, or change-control policy.
Quality consistency is especially important for excipients used in oral dosage forms. A buyer should ask how the supplier controls incoming raw materials, in-process checks, and final release testing. The point is not to collect paperwork for its own sake; it is to reduce the risk of batch drift and maintain product performance over time. If a supplier cannot clearly explain test methods or release criteria, that is a warning sign.
When compliance matters, I recommend verifying that the intended use matches the regulatory expectations in your destination market. For example, pharmaceutical use requirements may differ from nutraceutical or research-use requirements. If your product will be filed or registered, ask whether the supplier can support the relevant documentation package and long-term supply continuity. Source: FDA excipient resources; USP-NF; ICH quality principles for pharmaceutical materials.
In my experience, the real buying decision is often shaped by three commercial factors: price, minimum order quantity, and lead time. For Crospovidone XL 10, these can vary based on grade, packaging format, documentation requirements, and whether the order is for trial, pilot, or routine supply. Because of that, I would avoid comparing suppliers only on unit price.
Instead, compare the total sourcing package. A slightly higher price may be acceptable if the supplier offers better batch consistency, clearer documentation, and more reliable delivery timing. Conversely, a low-priced quote can become expensive if it creates formulation problems or delays your production schedule. Buyers should ask for pricing based on volume, packaging, and destination terms so the comparison is meaningful.
MOQ and lead time should also be confirmed early. For sample orders, suppliers may support small quantities for formulation testing. For commercial supply, it is smart to ask about production scheduling, inventory availability, and re-order timing. In practical procurement, lead time can be as important as price, especially if your line depends on uninterrupted excipient supply.
If I were screening a Crospovidone XL 10 supplier, I would use a simple checklist to reduce risk and speed up evaluation. This is especially useful when you are preparing an RFQ or comparing multiple vendors. The goal is to confirm technical fit, quality discipline, and supply reliability before committing to purchase.
It is also useful to ask how the supplier handles technical support. For example, can they discuss dosage level, blending order, or compatibility concerns? Can they help you compare one grade against another? Suppliers that understand application support can save you time during development and reduce unnecessary trial-and-error. That is often where a long-term sourcing relationship becomes valuable.
Its primary function is to help tablets disintegrate quickly after contact with liquid. This supports faster breakup of the dosage form and can improve release behavior. In many formulations, it is used as a superdisintegrant.
It can be suitable for direct compression if the full formula is designed for that process. However, suitability depends on flowability, compressibility, and the other excipients in the blend. I always recommend pilot testing before full-scale production.
At a minimum, request COA, SDS, and TDS. If your market needs it, ask for additional regulatory or compliance documents. It is also wise to confirm packaging, shelf life, and storage conditions before ordering.
Check the technical data sheet and compare the physical properties against your process needs. Then test a sample in your actual formulation under your normal compression or blending conditions. This is the best way to confirm fit.
Yes, and I strongly recommend it. A sample lets you verify handling, disintegration behavior, and documentation quality before you place a larger order. It is the safest way to reduce sourcing risk.
Crospovidone XL 10 is a functional superdisintegrant used to improve tablet breakup, support fast disintegration, and help oral solid dosage formulations perform more consistently. If you are evaluating it for procurement, the most important checks are specification fit, application suitability, documentation, and supplier consistency. In other words, the right grade is not only about performance in the lab; it is also about whether the material can be supplied reliably at the quality level your project needs.
My recommendation is to start with a clear application target, request a sample and full technical documents, and then compare the grade under your actual process conditions. If you are preparing an RFQ, ask for specification confirmation, sample support, and a commercial quotation together so you can evaluate both technical and sourcing fit at the same time. If you need a supplier discussion, I can help you structure the inquiry around the exact parameters that matter most.
If you are sourcing Crospovidone XL 10 for formulation, pilot testing, or routine supply, I recommend starting with a technical confirmation before purchase. You can request a quote, ask for sample, and contact for specification confirmation so I can help align the material with your application needs. For B2B projects, this is usually the fastest way to reduce risk and improve buying accuracy.
At Yuking, I support buyers who need reliable excipient sourcing, technical communication, and practical procurement guidance. If you share your application, target dosage form, and required documents, I can help you move from initial interest to a more accurate buying decision.
Want more information on crospovidone xl 10? Feel free to contact us.